GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A3452 GW-11002 CitationSummary: GPR40 antagonist
-
A3895 TUG-770Target: Free Fatty Acid ReceptorsSummary: FFA1/GPR40 agonist
-
A8439 GSK1292263Summary: Novel GPR119 agonist
-
A1709 GW9508Target: Free Fatty Acid ReceptorsSummary: FFA1/GPR40 agonist,potent and selective
-
A8339 TAK-875Target: GPR40Summary: GPR40 agonist
-
B5669 4-CMTBSummary: FFA2 agonist
-
B7792 AH 76141 CitationTarget: Free Fatty Acid ReceptorsSummary: FFA4/GPR120 antagonist
-
B7793 GSK 137647Summary: FFA4/GPR120 agonist
-
B7499 TUG 424Summary: FFA1 (GPR40) agonist
-
B7691 MEDICA 16Summary: Free fatty acid 1 (FFA1/GPR40) receptor agonist